Long-term Efficacy and Safety, Including COVID-19 Infections, Among Ozanimod-Treated Patients With Relapsing Multiple Sclerosis in the DAYBREAK Open-Label Extension Trial

被引：0

作者：

Cree, B. A. ^{[1
]}

Selmaj, K. W. ^{[2
]}

Steinman, L. ^{[3
]}

Comi, G. ^{[4
]}

Bar-Or, A. ^{[5
]}

Arnold, D. L. ^{[6
]}

Hartung, H. ^{[7
,8
,9
]}

Montalban, X. ^{[10
]}

Havrdova, E. K. ^{[11
,12
]}

Sheffield, J. K. ^{[13
]}

Minton, N. ^{[13
]}

Cheng, C. ^{[13
]}

Silva, D. ^{[13
]}

Kappos, L. ^{[14
,15
,16
,17
,18
]}

Cohen, J. A. ^{[19
]}

机构：

[1] Weill Inst Neurosci, San Francisco, CA USA

[2] Univ Warmia & Mazury, Ctr Neurol & Coll Med, Lodz, Poland

[3] Stanford Univ, Dept Neurol & Neurol Sci, Beckman Ctr Mol Med, Med Ctr, Stanford, CA 94305 USA

[4] Vita Salute San Raffaele Univ & Casa Cura Policli, Milan, Italy

[5] McGill Univ, Philadelphia, PA USA

[6] Montreal Neurol Inst, Neurol & Neurosurg, Montreal, PQ, Canada

[7] Heinrich Heine Univ, Fac Med, Dept Neurol, Dusseldorf, Germany

[8] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia

[9] Med Univ Vienna, Dept Neurol, Dusseldorf, Germany

[10] Hosp Univ Vall dHebron, Dept Neurol Neuroimmunol, Ctr dEsclerosi Multiple Catalunya Cemcat, Barcelona, Spain

[11] Charles Univ Prague, Med Fac 1, Dept Neurol, Prague, Czech Republic

[12] Charles Univ Prague, Med Fac 1, Ctr Clin Neurosci, Prague, Czech Republic

[13] Bristol Myers Squibb, Princeton, NJ USA

[14] Univ Hosp, Dept Med, Res Ctr Clin Neuroimmunol & Neurosci, Basel, Switzerland

[15] Univ Hosp, Dept Clin Res, Res Ctr Clin Neuroimmunol & Neurosci, Basel, Switzerland

[16] Univ Hosp, Dept Biomed, Res Ctr Clin Neuroimmunol & Neurosci, Basel, Switzerland

[17] Univ Hosp, Dept Biomed Engn, Res Ctr Clin Neuroimmunol & Neurosci, Basel, Switzerland

[18] Univ Basel, Basel, Switzerland

[19] Cleveland Clin, Mellen Ctr MS Treatment & Res, Cleveland, OH USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 1_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P142

引用

页码：85 / 86

页数：2

共 50 条

[21] Baseline Predictors of Long-Term Disability Progression in Ozanimod-Treated Participants With Relapsing Multiple Sclerosis
Hartung, Hans-Peter
DeLuca, John
Granziera, Cristina
Filippi, Massimo
Kappos, Ludwig
Cheng, Chun-Yen
Pachai, Chahin
Riolo, Jon
DeBoer, Erik
Silva, Diego
Penner, Iris-Katharina
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 354 - 355
[22] Safety patterns with ozanimod during phase 3 and open-label extension trials in patients with relapsing multiple sclerosis
Selmaj, K. W.
Ziemssen, T.
Comi, G.
Hartung, H. -P.
Singal, M.
Riolo, J. V.
Cheng, C. -Y.
Sheffield, J. K.
Minton, N.
Vermersch, P.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 641 - 642
[23] Long-term Safety and Tolerability of Ozanimod by Age Category in Patients With Relapsing Multiple Sclerosis From Two Phase 3 Trials and an Open-Label Extension Study
Selmaj, K. W.
Cohen, J. A.
Steinman, L.
Comi, G.
Bar-Or, A.
Hartung, H.
Montalban, X.
Kappos, L.
Sheffield, J. K.
Krakovich, A.
Cheng, C.
Riolo, J.
Silva, D.
Cree, B. A.
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 56 - 57
[24] Safety of Concurrent Administration of Serotonergic Antidepressants and Ozanimod in Participants With Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study
Naismith, Robert
Cohen, Jeffrey
Bar-Or, Amit
Comi, Giancarlo
Selmaj, Krzysztof
Hartung, Hans-Peter
Sheffield, James
Cheng, Chun-Yen
Riolo, Jon
Krakovich, Anthony
Reardon, Jennifer
Cree, Bruce A. C.
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1029 - 1030
[25] Safety of Evobrutinib in Patients With Relapsing Multiple Sclerosis is Maintained in a Long-term Open-label Extension of a Phase II Study
Montalban, Xavier
Arnold, Douglas L.
Weber, Martin S.
Staikov, Ivan
Piasecka-Stryczynska, Karolina
Martin, Emily C.
Mandel, Matthew
Zima, Yulia
Shaw, Jamie
Dangond, Fernando
Grenningloh, Roland
Li, Ying
Tomic, Davorka
Wolinsky, Jerry S.
NEUROLOGY, 2021, 96 (15)
[26] Absolute Lymphocyte Count Around Infections During Phase 3 and Open-Label Extension Trials of Ozanimod in Participants With Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study
Hartung, Hans-Peter
Steinman, Lawrence
Bar-Or, Amit
Sheffield, James
Cheng, Chun-Yen
Riolo, Jon
Harris, Sarah
Reardon, Jennifer
Thorpe, Andrew
Cree, Bruce A. C.
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1016 - 1017
[27] Long-term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial
Freedman, M.
Wolinsky, J.
Comi, G.
Kappos, L.
Olsson, T.
Miller, A.
Benamor, M.
Dukovic, D.
Liang, J.
Truffinet, P.
O'Connor, P.
MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 225 - 225
[28] Correlations Between Early MRI Parameters and Long-term Clinical Outcomes in Phase 3 and Open-label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis
Arnold, Douglas L.
Freeman, Leorah
Hartung, Hans-Peter
Montalban, Xavier
Cohen, Jeffrey A.
Bar-Or, Amit
Steinman, Lawrence
DeLuca, John
Cheng, Chun-Yen
Riolo, Jon V.
Silva, Diego
Pachai, Chahin
Cree, Bruce A. C.
NEUROLOGY, 2023, 100 (17)
[29] Correlations between early MRI parameters and long-term clinical outcomes in phase 3 and open-label extension studies of ozanimod in relapsing multiple sclerosis
Arnold, D. L.
Freeman, L.
Hartung, H. -P.
Xavier Montalban, X.
Cohen, J. A.
Bar-Or, A.
Steinman, L.
DeLuca, J.
Cheng, C. -Y.
Riolo, J. V.
Silva, D.
Pachai, C.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 377 - 378
[30] Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: An open-label extension trial
McConville, B
Carrero, L
Sweitzer, D
Potter, L
Chaney, R
Foster, K
Sorter, M
Friedman, L
Browne, K
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2003, 13 (01) : 75 - 82

← 1 2 3 4 5 →